TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04610229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation guioded by dose painting
Description: 1
Study: NCT00922636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Taken in tablet form QD po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Taken in tablet form QD po.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Taken in tablet form QD po.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (tablet)
Description: Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (capsule)
Description: Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
Study: NCT03834311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: isokinetic strengthening
Description: isokinetic upper extremity (forearm) strengthening for 4 weeks 3d/w

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise band strengthening
Description: upper extremity (forearm) strengthening with exercise band 4 weeks 3d/w
Study: NCT02359110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive placebo tab less than 1 hour before surgery
Study: NCT01026025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duet TRS
Description: This is a single arm study.
Study: NCT01561937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
Study: NCT03831776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (\> 300 mg/d \> 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon
Description: Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
Study: NCT00738712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Magnetic Resonance Imaging
Description: MRI
Study: NCT03110354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3201b
Description: DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
Study: NCT03278574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Description: Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring annuloplasty with posterior band
Description: Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ring annuloplasty with complete ring
Description: Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
Study: NCT03482050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstroRx
Description: Astrocytes derived from human embryonic stem cells
Study: NCT01348126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of ganetespib and docetaxel
Description: Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
Study: NCT04643132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine (low-dose)
Description: After the induction of anesthesia, S-ketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h S-ketamine until starting skin suture.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine (high-dose)
Description: After the induction of anesthesia, S-ketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h S-ketamine until starting skin suture.
Study: NCT01799759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile

Intervention type: OTHER
Group type: OTHER
Intervention: Completion of instruments only
Description: Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
Study: NCT01092013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training on laparoscopic simulator in skills lab
Description: Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training at actual laparoscopic surgery
Description: Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical instruction
Description: Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Technical instruction
Description: Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
Study: NCT04321928

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized health education
Description: Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General health education
Description: Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.
Study: NCT02746835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program for fall prevention
Description: Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility.
Study: NCT03017820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT03316586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib may help to shrink or stabilize breast cancer
Study: NCT01065753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Diet control with exercise
Study: NCT03082508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl
Description: Algisyl device (implants) administered during a surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: as per protocol
Study: NCT01037426

Intervention type: OTHER
Group type: OTHER
Intervention: Fill out Questionnaire
Description: Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~* History of falls and fractures during the 12 months before pacemaker implantation~* Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~* History of falls and fractures during the 12 months after pacemaker implantation~* Medical and Arrhythmia History~* Cardiovascular Events~* Cardiovascular Medication~* Device programming information
Study: NCT03017820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT02536937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT01016743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
Study: NCT03563157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin Hydrochloride
Description: Aldoxorubicin Hydrochloride HCI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-\[HER2\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: haNK™, NK-92 \[CD16.158V, ER IL-2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: BAVENCIO® injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: XELODA® tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: ERBITUX® injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU; Fluorouracil Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin Calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: ELOXATIN® injection
Study: NCT02536937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00228163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide (HMR1726)
Description: tablet, oral administration once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide (HMR1726)
Description: tablet, oral administration once daily.
Study: NCT02309086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells transduced with Ad encoding NS3
Description: Patients will receive 3 different dosis of the vaccine via subcutaneous injection
Study: NCT02696824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Adherence and Depression
Description: This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach.
Study: NCT03563157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: STIVARGA® tablets
Study: NCT02402517

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small particle size pea flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large particle size pea flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Pulse extruded snack
Study: NCT03563157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: STIVARGA® tablets

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy
Study: NCT02402517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navy bean flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto bean flour
Description: Pulse extruded snack
Study: NCT00004246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Days 1-5 for 7 weeks
Study: NCT02814071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Description: Early enteral feeding as per description
Study: NCT02558049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
Study: NCT02824107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires for psychosocial factors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires for psychosocial factors
Study: NCT05088772

Intervention type: DEVICE
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy performed at 100% oxygen at 2.0-2.4 ATA, with 1-3 air breaks, typically at 5 sessions per week, with limited variation depending on the treatment indication and patient/clinician preference.
Study: NCT03944616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Beverage
Description: Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
Study: NCT03535961

Intervention type: DRUG
Group type: OTHER
Intervention: apatinib+oral etoposide
Description: apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
Study: NCT01193946

Intervention type: DIETARY_SUPPLEMENT
Intervention: dietary control
Description: Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
Study: NCT01111565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.
Study: NCT02539251

Intervention type: BEHAVIORAL
Intervention: Arabic ASQ -3
Description: Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
Study: NCT05145985

Intervention type: DIAGNOSTIC_TEST
Intervention: Senior Fitness Test
Description: Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)
Study: NCT02624999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax™
Description: AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
Study: NCT04142359

Intervention type: BIOLOGICAL
Intervention: BCG in Combination with N-803
Description: BCG in Combination with N-803

Intervention type: BIOLOGICAL
Intervention: BCG in Combination with N-803
Description: BCG in Combination with N-803

Intervention type: DRUG
Intervention: N-803 alone
Description: N-803 alone